Exelixis, Inc. (EXEL) VP Sells $22,181.67 in Stock

Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 959 shares of the stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $23.13, for a total value of $22,181.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Patrick J. Haley also recently made the following trade(s):

  • On Monday, February 25th, Patrick J. Haley sold 4,272 shares of Exelixis stock. The shares were sold at an average price of $22.27, for a total value of $95,137.44.
  • On Monday, February 11th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $21.30, for a total value of $21,300.00.
  • On Wednesday, January 9th, Patrick J. Haley sold 1,560 shares of Exelixis stock. The shares were sold at an average price of $23.50, for a total value of $36,660.00.
  • On Monday, January 7th, Patrick J. Haley sold 5,560 shares of Exelixis stock. The shares were sold at an average price of $21.51, for a total value of $119,595.60.
  • On Wednesday, January 9th, Patrick J. Haley sold 9,120 shares of Exelixis stock. The stock was sold at an average price of $22.18, for a total value of $202,281.60.
  • On Thursday, January 3rd, Patrick J. Haley sold 8,000 shares of Exelixis stock. The stock was sold at an average price of $19.95, for a total value of $159,600.00.

Shares of NASDAQ:EXEL traded down $0.03 during trading on Friday, hitting $24.73. The stock had a trading volume of 88,563 shares, compared to its average volume of 4,070,967. Exelixis, Inc. has a 12 month low of $13.42 and a 12 month high of $25.27. The firm has a market capitalization of $7.45 billion, a P/E ratio of 17.33, a P/E/G ratio of 0.77 and a beta of 2.22. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.41 and a current ratio of 8.50.



Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 12th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.14. Exelixis had a return on equity of 48.90% and a net margin of 80.95%. The firm had revenue of $228.60 million during the quarter, compared to analyst estimates of $188.44 million. During the same quarter in the prior year, the company earned $0.12 EPS. The business’s revenue was up 90.4% compared to the same quarter last year. On average, equities analysts forecast that Exelixis, Inc. will post 1.04 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the company. MUFG Securities EMEA plc bought a new position in shares of Exelixis in the 4th quarter worth approximately $3,934,000. Geode Capital Management LLC raised its position in shares of Exelixis by 7.5% in the 4th quarter. Geode Capital Management LLC now owns 3,009,454 shares of the biotechnology company’s stock worth $59,195,000 after acquiring an additional 210,181 shares in the last quarter. Norges Bank bought a new position in shares of Exelixis in the 4th quarter worth approximately $54,640,000. Dimensional Fund Advisors LP raised its position in shares of Exelixis by 11.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,381,432 shares of the biotechnology company’s stock worth $27,172,000 after acquiring an additional 144,741 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in shares of Exelixis by 18.9% in the 4th quarter. Nordea Investment Management AB now owns 264,435 shares of the biotechnology company’s stock worth $5,201,000 after acquiring an additional 41,955 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

EXEL has been the subject of several research analyst reports. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a report on Monday, December 17th. BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a report on Wednesday, January 9th. Cowen reiterated a “buy” rating and issued a $29.00 price objective on shares of Exelixis in a report on Tuesday, February 26th. Oppenheimer set a $40.00 price objective on Exelixis and gave the stock a “buy” rating in a report on Thursday, November 15th. Finally, ValuEngine upgraded Exelixis from a “sell” rating to a “hold” rating in a report on Wednesday, January 9th. One analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $29.20.

ILLEGAL ACTIVITY WARNING: “Exelixis, Inc. (EXEL) VP Sells $22,181.67 in Stock” was originally posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://dakotafinancialnews.com/2019/03/15/exelixis-inc-exel-vp-sells-22181-67-in-stock.html.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Further Reading: SEC Filing

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.